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The management of diabetes mellitus (DM) demands accurate 
assessment of glycaemic control to determine the efficacy of 
treatment. For decades, glycated haemoglobin (HbA1c) has been a 
surrogate marker to monitor the control of glycaemia and predict 
the risk of microvascular complications in patients with DM.[1,2] The 
Diabetes Control and Complications Trial (DCCT) showed that 
intensive glycaemic control significantly reduced the risk of long-
term microvascular complications for patients with type 1 DM.[3] 
Similar findings were subsequently reported for patients with type 
2 DM.[4] HbA1c values reflect mean blood glucose (MBG) during 
the preceding 2 - 3 months, making it a good marker for long-term 
assessment of glycaemic control.[4,5]
The American Diabetic Association (ADA) recommends self-
monitoring of blood glucose and HbA1c as the two techniques to 
assess glycaemic control. Self-monitoring of blood glucose forms an 
important component of glucose monitoring in patients with DM, 
especially those taking insulin therapy, for adjustment of therapy and 
to prevent hypoglycaemic episodes.[5]
Patient participation is critical in diabetes care, and most patients 
are familiar with glucose levels and may find it difficult to relate 
HbA1c values to glucose levels. This problem has led to the derivation 
of a regression equation for calculating the estimated average glucose 
(eAG) from the HbA1c value, following the demonstration of a linear 
relationship between HbA1c values and MBG levels.[6] However, 
to date numerous regression equations have been formulated by 
many studies,[7] with published data showing substantial variation 
in individual MBG for a given HbA1c value.[8,9] Most commonly 
used is Nathan’s regression equation, derived using data from the 
A1c-Derived Average Glucose (ADAG) Study Group,[6] previously 
adopted by the ADA[10] and now implemented in most laboratories. 
It was hoped that patients would understand the changes in their 
HbA1c better if they could relate them to eAG.
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Background. Glycated haemoglobin (HbA1c) has been used for decades as a measure of chronic glycaemia. A simple linear relationship 
between HbA1c values and mean blood glucose (MBG) has been identified and led to conversion of HbA1c values into estimated average 
glucose (eAG) levels, following the findings of the A1c-Derived Average Glucose (ADAG) Study Group. The intention was to help patients 
with diabetes mellitus (DM) understand their glycaemic control better, as eAG is reported in the same units as self-monitored glucose levels. 
However, factors other than glycaemia have been found to affect the relationship between HbA1c and MBG.
Objectives. To: (i) determine the relationship between self-monitored MBG levels and HbA1c values; and (ii) evaluate the correlation 
between MBG levels and eAG levels calculated from HbA1c values using the regression equation derived from the ADAG Study Group in 
black South African patients with DM.
Methods. This was a prospective observational study of 96 diabetic patients. MBG levels were calculated using glucose measurements 
downloaded from the glucose meters for the previous 90 days (3 months). High-performance liquid chromatography was used for 
measurement of HbA1c values, collected at the end of 3 months. eAG was calculated using the regression equation from the ADAG Study 
Group, as follows: eAG (mmol/L) = 1.5944 × HbA1c (NGSP, %) – 2.594. 
Results. A positive correlation was found between MBG and HbA1c in all participants (R2=0.69, p<0.0001). There was a wide range of MBG 
levels for any given HbA1c value. Clinically significant differences between MBG and eAG were found, with a ≥10% difference in 65.6% of 
the participants. eAG overestimated MBG in ~71.8% of the study population, with an overestimation of ≥1.6 mmol/L (28.7 mg/dL, equivalent 
to a 1% change in HbA1c value) in ~50% of the total study population.
Conclusions. Our findings showed an imperfect relationship between MBG levels and HbA1c values. eAG significantly overestimated 
MBG, and this disagreement may cause confusion among both patients and clinicians. The risk of hypoglycaemic episodes may also increase 
if HbA1c and eAG alone are used to intensify therapy. We recommend that the use of eAG should be validated prior to implementation in 
clinical practice. It would be ideal to evaluate the relationship between average glucose and HbA1c in each individual patient in order to 
provide more personalised diabetes care.
S Afr Med J 2020;110(5):416-421. https://doi.org/10.7196/SAMJ.2020.v110i5.13959
417       May 2020, Vol. 110, No. 5
RESEARCH
While eAG may improve patients’ participation in their diabetic 
control, the mean value determined from daily capillary glucose 
monitoring may or may not correlate with the eAG calculated 
from the HbA1c value. If these two values differ, patients are likely 
to become confused about their glycaemic status. This possibility 
should be considered before providing the patient with eAG levels at 
their follow-up visit, to avoid confusion.
We determined the relationship between self-monitored MBG 
levels and HbA1c values and the correlation between MBG and 
HbA1c-derived eAG using the equation from the ADAG Study 
Group.
Methods
Participants
This observational study was conducted in the diabetes clinic at 
Dr George Mukhari Academic Hospital, Pretoria, South Africa. 
Data were collected between October 2017 and January 2018. One 
hundred and thirty-six patients with DM were initially enrolled in 
the study. Pregnant women and patients who had conditions such 
as anaemia, reticulocytosis, chronic renal or liver failure, blood loss 
and/or transfusion, haemoglobinopathies, or iron, vitamin B12 and 
folate deficiencies, as well as those on high-dose vitamin C, steroids 
or erythropoietin therapy, were excluded from the study.
We excluded 40 patients from the study owing to a history of 
chronic kidney disease with associated anaemia of chronic disease 
(n=32) and anaemia due to iron and vitamin B12 deficiencies (n=8). 
The remaining 96 patients were evaluated. The study was approved 
by the institutional ethical committee (ref. no. MREC/P/241/2014), 
and informed consent was obtained from all participants.
Glycated haemoglobin assay
Blood for HbA1c testing was collected in ethylenediaminetetra- acetic 
acid specimen tubes on the day of the clinic visit. HbA1c values were 
measured by ion-exchange high-performance liquid chromatography 
using the VARIANT II TURBO system (Bio-Rad Laboratories, 
USA). The analytical coefficient of variation (CV) of the assay for 
the duration of the study was 0.8% in National Glycohemoglobin 
Standardization Program (NGSP) units and 1.2% in SI units. This 
method is certified by the NGSP and is traceable to the DCCT.
Mean blood glucose determination
Self-monitoring capillary glucose measurements were done using the 
On Call Plus device (On Call Plus Blood Glucose Monitoring System, 
USA). The day-to-day CV claimed by the manufacturer ranged from 
3.3% to 5.0%, assessed using glucose levels ranging from 1.7 mmol/L 
to 28 mmol/L. Most participants measured their capillary blood 
glucose twice a day, in the morning before meals and at bedtime. 
All participants who tested at least once a day were included in the 
study. Of patients who did fewer glucose tests, only those who tested 
at least once a day in the month (30 days) preceding their clinic visit 
were included. A strong correlation has been reported between MBG 
levels (measured during the preceding month) and HbA1c values. [2] 
Glucose results were downloaded from the device on the day of 
the clinic visit. The MBG levels were determined by calculating the 
average value of all the glucose measurements downloaded from the 
glucose device for the previous 90 days (3 months).
Estimated average glucose calculation
The eAG was calculated from the HbA1c (%) results using the 
equation derived from the ADAG Study Group: eAG (mmol/L) = 
1.5944 × HbA1c (NGSP, %) – 2.594, (R2=0.84, p<0.0001).[6]
Statistical analysis
All statistical analyses were performed using the Statistical Package 
for the Social Sciences (SPSS, version 11.0 for Windows; IBM, USA). 
The Kolmogorov-Smirnov test was used to evaluate the distribution 
of the variables. The linear regression model was applied to estimate 
the relationship between HbA1c and MBG, and Spearman’s test was 
used to assess the correlation between the two parameters. A two-
tailed p-value <0.05 was accepted as significant.
The influence of age, gender, type of DM, history of smoking, 
alcohol use, insulin therapy, hypertension, socioeconomic status 
and level of education on the relationship between MBG and 
HbA1c was examined by comparing the slope (MBG v. HbA1c) 
among the individual subgroups using Fisher Z-transformation 
(z-observations). Predicted MBG was calculated from HbA1c values 
based on the regression analysis between MBG and HbA1c.
Agreement between MBG and eAG levels was assessed using 
Bland-Altman analysis. The limits of agreement (LOA) were set 
at the internationally accepted maximum error limit of ±10%.[11] 
The absolute and percentage differences between eAG and MBG 
were also calculated for each individual to determine their clinical 
significance.
Results
Characteristics of the study cohort
The study group consisted of 96 black diabetic patients with a 
median age of 62 years (range 14 - 88 years), of whom 88.5% had 
type 2 DM and 64.6% were female. The number of capillary glucose 
measurements ranged from 45 to 297 per participant, with a total of 
12 370 glucose tests during the 3-month period. The frequency of 
glucose testing per day, prior to the measurement of HbA1c at day 
90, is shown in Fig. 1. Baseline characteristics of the whole cohort are 
shown in Table 1. The distributions of age, HbA1c, MBG and eAG 
were abnormal (p<0.05).
Correlation between MBG and HbA1c
A positive correlation was found between MBG and HbA1c in all 
participants (R2=0.69; p<0.0001) (Fig. 2). The slope of MBG levels v. 
HbA1c values was 1.20 mmol/L per 1% HbA1c with an intercept of 
0.49 mmol/L, and the Spearman’s correlation coefficient (r) was 0.83 
(Fig. 2). Factors such as age, gender, smoking status, type of DM, 
history of alcohol use and insulin therapy as well as socioeconomic 
status and patient’s level of education did not meaningfully affect the 
slope for MBG v. HbA1c.
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Fig. 1. Frequency of capillary glucose testing per day in the whole study popu­
lation.
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Predicted MBG levels calculated from 
HbA1c values based on the regression 
equation from the present study are shown 
in Table 2, in both conventional and SI units 
with 95% confidence intervals (CIs).
Agreement between MBG and eAG
The characteristics of the present study 
compared with the ADAG Study Group 
are shown in Table 3. The slope and 
the intercept of the regression equation 
correlating MBG to HbA1c in our study 
were lower than those found by the ADAG 
Study Group.
A Bland-Altman plot was used to assess 
the agreement between eAG and MBG 
(Fig. 3). The whole-group average of MBG 
and eAG was depicted on the x-axis, with 
the percentage difference between the two 
parameters on the y-axis. The percentage 
difference was determined by dividing the 
absolute value of the difference between 
eAG and MBG (eAG – MBG) by the average 
of the two parameters [(eAG + MBG)/2)], 
multiplied by 100. The LOA were set at the 
internationally accepted maximum error 
limit of ±10%.
Poor agreement was observed between 
MBG and eAG. Most results (65.6%) fell 
outside the limits of agreement (Fig.  3). 
eAG overestimated MBG in 74.0% of 
participants, and underestimated MBG 
in 24.2%. The overestimation and under-
estimation of MBG was clinically significant 
(percentage difference ≥10%) in 56.3% and 
9.4%, respectively. Table 4 shows the total 
number of participants with a clinically 
significant difference between MBG and 
eAG.
The slope of the regression equation in 
the ADAG study was 1.6 mmol/L (28.7 mg/
dL) of glucose for every 1% change in 
HbA1c, so a difference between MBG and 
eAG of 1.6 mmol/L (28 mg/dL) would be 
equivalent to a difference of 1% HbA1c. 
A difference of ≥0.5% HbA1c represents a 
statistically significant change in glycaemic 
control. In this study, 71.8% of participants 
had a difference of ≥0.5% HbA1c, which 
was represented by an absolute difference 
of ≥0.8 mmol/L (14.4 mg/dL) between eAG 
and MBG (Table 5).
Discussion
Our study supports the notion of a linear 
relationship between HbA1c values  and 
MBG, but the correlation was poor 
(R2=0.69) compared with other studies that 
showed a strong relationship – Nathan et 
al.[6] (R2=0.84) and Makris et al.[12] (R2=0.86). 
The slope of the regression equation in our 
study was 1.2 mmol/L (21.7 mg/dL) glucose 
Table 1. Baseline characteristics
Parameters Total population Type 1 DM Type 2 DM
n (%) 96 (100) 11 (11.5) 85 (88.5)
Age (years), median (IQR)/mean (SD) 62.0 (50.3 - 67.8) 19.5 (4.8) 63 (57.5 - 69)
Sex female, n (%) 62 (64.6) 8 (72.7) 54 (63.5)
Hb (g/dL), mean (SD) 13.8 (0.02) 13.8 (0.02) 13.7 (0.03)
HbA1c (%), median (IQR)/mean (SD) 8 (6.9 - 11.4) 8.8 (2.6) 7.9 (6.9 - 10.2)
HbA1c (mmol/mol), median (IQR)/mean (SD) 64 (52 - 101) 72.2 (28.6) 63 (52 - 88)
eAG (mmol/L), median (IQR)/mean (SD) 10.2 (8.4 - 15.6) 11.4 (4.2) 10 (8.4 - 13.7)
MBG (mmol/L), median (IQR)/mean (SD) 9.2 (7.3 - 9.2) 10.1 (4.0) 9 (7.2 - 12)
Smoker, n (%) 6 (6.3) 0 6 (6.3)
Alcohol use, n (%) 10 (10.4) 0 10 (10.4)
Insulin therapy, n (%) 75 (78.1) 11 (100) 64 (75.3)
DM = diabetes mellitus; IQR = interquartile range; SD = standard deviation; Hb = haemoglobin; HbA1c = glycated haemoglobin; eAG = estimated average glucose (mmol/L) = 1.5944 × HbA1c 
(NGSP, %) – 2.594; MBG = mean blood glucose; NGSP = National Glycohemoglobin Standardization Program.
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Fig. 2. MBG v. HbA1c. MBG measured by glucose meter over a period of 3 months (90 days), HbA1c 
measured at the end of month 3. The regression line was calculated using least squares. (MBG = mean 
blood glucose; HbA1c = glycated haemoglobin.)
Table 2. Predicted MBG for HbA1c values
MBG
HbA1c (%) mmol/L, mean  (95% CI)* mg/dL, mean  (95% CI)†
5 5.5 (3.1 - 7.9) 99 (56 - 143)
6 6.7 (4.2 - 9.3) 121 (75 - 167)
7 7.9 (5.2 - 10.7) 142 (93 - 192)
8 9.1 (6.2 - 12.0) 164 (112 - 216)
9 10.3 (7.3 - 13.4) 186 (130 - 241)
10 11.5 (8.3 - 14.8) 207 (149 - 266)
11 12.7 (9.3 - 16.1) 229 (168 - 290)
12 13.9 (10.4 - 17.5) 250 (186 - 315)
MBG = mean blood glucose; HbA1c = glycated haemoglobin; CI = confidence interval.
*Linear regression: MBG (mmol/L) = 1.2 × HbA1c – 0.5.
†Linear regression: MBG (mg/dL) = 21.6 × HbA1c – 8.8. 
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for every 1% change in HbA1c. This value 
is similar to the results of other studies 
that used continuous glucose monitoring 
(CGM) devices,[8,9] but is lower than the 
value reported by Rofhling et al.[13] in 
a study analysing data from the DCCT 
(slope of 36 mg/dL (2 mmol/L)) and by the 
ADAG Study Group[6] (slope of 28.7 mg/
dL (1.6  mmol/L)). This means that in our 
study population, smaller changes in glucose 
concentrations translate to large differences 
in HbA1c values.
There was a wide range of MBG levels for 
any given HbA1c value in the present study. 
For example, the MBG ranged from 6.0 to 
8.2 mmol/L (107.9 - 138.3 mg/dL) for an 
HbA1c of 7% (n=7) (Fig. 2), suggesting an 
imperfect relationship between MBG and 
HbA1c. Factors such as age, gender, smoking 
status, type of DM, history of alcohol use and 
insulin therapy, as well as socioeconomic 
status and patient level of education, did 
not meaningfully affect the slope for MBG 
v. HbA1c.
An imperfect relationship between MBG 
and HbA1c is also demonstrated by the 
predicted MBG levels for HbA1c values 
derived from the regression equation (MBG 
v. HbA1c of the total study population), 
which showed a wide range in predicted 
MBG levels for any given HbA1c value 
(Table 2). The predicted MBG levels also 
showed an overlap between HbA1c values. 
For example, at an HbA1c value of 7%, the 
predicted MBG was 7.9 mmol/L with a 95% 
CI ranging from 5.2 to 10.7 mmol/L, which 
overlaps with the 95% CI of the MBG at 
HbA1c of 8% (6.2 - 12.0 mmol/L) (Table 2).
The poor correlation observed in our 
study could be due to inaccurate calculation 
of the MBG, either from infrequent 
measurements of blood glucose or portable 
meter inaccuracies. The majority of the 
study participants were elderly (55% of the 
study population were aged >60 years), and 
they may have struggled with the capillary 
glucose measurements or used improper 
measurement techniques, even though they 
received prior training. However, other 
studies that incorporated the use of CGM, 
which offers the most accurate assessment of 
glycaemia, also reported a poor correlation 
between HbA1c and MBG, supporting the 
notion that the discrepancy could be due to 
biological variation in erythrocyte survival 
or glycation rates.[8,9,13-15]
Numerous authors have hypothesised that 
the rate of glycation is not constant, and that 
even at the same MBG the glycation rate may 
differ between individuals, as some patients 
are high glycators while others are low 
glycators. Even if they have the same MBG, 
the high glycators will have much higher 
HbA1c than the low glycators.[15] Racial 
and ethnic differences in the relationship 
between HbA1c levels and average 
glycaemia have also been reported, and non-
glycaemic factors affecting haemoglobin 
glycation, differences in red cell survival, 
and the balance of glucose between the 
extracellular and intracellular red blood 
cell environment have been postulated as 
probable contributing factors.[16-20]
The second objective of our study was 
to evaluate the application of the HbA1c-
derived eAG (ADAG equation) in our 
study population. Disagreement between 
MBG and eAG was observed (Fig. 3). We 
found clinically significant differences 
between MBG and eAG (Table 4), with 
MBG significantly overestimated in 56.3% 
of the total number of participants and 
underestimated in 9.4%. Further analysis 
showed that eAG overestimated MBG by 
≥0.8 mmol/L (14.4 mg/dL, equivalent to a 
0.5% change in HbA1c value) in ~71.8% of 
all participants (Table 5). A 0.5% change in 
HbA1c represents a statistically significant 
change in glycaemic control.[21,22] If HbA1c 
and eAG alone are used to adjust anti-
glycaemic therapy, there would therefore be 
an increased risk of hypoglycaemic episodes.
The differences in the study designs 
between the ADAG study and the present 
study may have attributed to the observed 
poor correlation between MBG and eAG. 
Firstly, 83% of the ADAG study participants 
were white and only 8% were African 
American, whereas only black South 
Africans were included in our study. The 
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Fig. 3. Bland­Altman plot of the whole group. (eAG = estimated average glucose (mmol/L) = 1.5944 × 
HbA1c (NGSP, %) – 2.594); MBG = mean blood glucose; NGSP = National Glycohemoglobin Standard­
ization Program.)
Table 3. Characteristics of the present study v. the ADAG Study Group[6]
Subjects 
(N) Ethnic group
HbA1c range 
(%), mean (SD) Method 
Curve fit 
(R2)
Slope (mmol/L 
(mg/dL))
Intercept (mmol/L 
(mg/dL))
Present study 96 100% black African 9.0 (2.8) Infrequent discrete 
testing
Linear 
(0.69)
1.20 (21.6) 0.49 (8.8)
ADAG Study Group 507 83% white, 8% 
African American, 
8% Hispanic,  
2% other
6.8 (1.3) Intermittent CGM Linear 
(0.84)
1.59 (28.7) 2.59 (46.7)
ADAG = A1c-Derived Average Glucose; CGM = continuous glucose monitoring.
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findings of the ADAG study suggested a different slope and intercept 
in the regression line (p=0.07) for African Americans, indicating that 
they may have slightly lower MBG levels for a given value of HbA1c. 
These findings are indeed in keeping with the overestimation of MBG 
by eAG (derived from the ADAG regression equation) observed in 
our study. The slope and intercept of the regression line found in our 
study are lower than those in the ADAG study (Table 3). Racial and 
ethnic variations in HbA1c have been reported.[16,20]
Secondly, the ADAG study population included both type 1 
and type 2 diabetic patients as well as non-diabetic participants. 
In contrast, our study population was composed of only diabetic 
patients (type 1 and type 2 DM). Lastly, only patients with stable 
glycaemia participated in the ADAG study, while there were no 
selection criteria in respect of glycaemic stability in our study group. 
As a result, the ADAG study-derived regression equation may be 
applicable only to patients with stable glycaemia.
The ADAG Study Group has recommended translation of HbA1c 
values to eAG levels in order to enable patients to understand their 
glycaemic status better, as it is reported in the same units as values 
obtained from patient self-monitoring.[6] Many laboratories today 
are reporting HbA1c results with eAG levels. In order to use eAG 
to reliably guide the management of diabetic patients, a fairly close 
agreement should exist between eAG and MBG in most patients. 
Our findings showed that eAG significantly overestimated MBG, 
and if HbA1c and eAG alone are used by clinicians to monitor 
glycaemic control and adjust therapy, there may therefore be 
an increased risk of hypoglycaemic episodes. The disagreement 
between MBG and eAG may also cause confusion in patients who 
self-monitor their MBG.
Study limitations
Limitations of this study include the use of glucose meters (discrete 
method) to determine MBG levels, which may have influenced 
the accuracy of MBG levels as a result of infrequent glucose 
measurements. The inclusion of participants who had a limited 
number of glucose tests (<1 test per day) may have also affected 
the accuracy of MBG levels for those participants. However, when 
these patients were excluded from analysis, there was no statistically 
significant difference in the slope of the regression line between MBG 
and HbA1c when data for the remaining participants were analysed 
(1.2 v. 1.1). Type 1 DM patients were under-represented in our study 
(11.5 %), so our findings may not be applicable to this group.
Conclusions
Our study has shown an imperfect relationship between MBG and 
HbA1c. Our findings disagree with the conclusions of the ADAG 
Study Group that a calculated mean glucose derived from HbA1c is 
clinically equivalent to self-monitored MBG. Our findings further 
suggest that in our population, eAG overestimated MBG in most 
participants. This disagreement may lead to confusion on the part of 
both patients and clinicians. The risk of hypoglycaemic episodes may 
also increase if HbA1c and eAG alone are used to intensify therapy. 
We recommend that the use of eAG should be validated prior to 
implementation in clinical practice.
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